Loading clinical trials...
Loading clinical trials...
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 162 With a Single Ascending Dose in Subjects With Chronic Hepatitis B Virus Infection
Conditions
Interventions
162
Placebo
Locations
1
Australia
Emeritus Research
Melbourne, Camberwell, Australia
Start Date
June 3, 2024
Primary Completion Date
July 9, 2024
Completion Date
July 9, 2024
Last Updated
July 16, 2024
NCT06537414
NCT06491563
NCT07515209
NCT01708889
Lead Sponsor
Yangshengtang Co., Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions